<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Phyllodes tumors of the breast
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Phyllodes tumors of the breast
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Phyllodes tumors of the breast
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ana M Grau, MD, FACS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            A Bapsi Chakravarthy, MD, FASTRO
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rashmi Chugh, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lori J Pierce, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel F Hayes, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anees B Chagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C)
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Wenliang Chen, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 13, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Phyllodes tumors are uncommon fibroepithelial breast tumors that are capable of a diverse range of biologic behaviors. In their least aggressive form, phyllodes tumors behave like benign fibroadenomas, although with a propensity to recur locally. At the other end of the spectrum, malignant phyllodes tumors can metastasize distantly, sometimes degenerating histologically into sarcomatous lesions that lack an epithelial component [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         The term "phyllodes," which means leaf-like, describes the typical papillary projections that are seen on pathologic examination. Although they were originally called "cystosarcoma phyllodes" by Johannes Müller in 1838 [
         <a href="#rid2">
          2
         </a>
         ], phyllodes tumors only occasionally have cystic components and are not true sarcomas by either cellular origin or biologic behavior. The terminology has since evolved, with over 60 synonyms having been applied to this entity before the term "phyllodes tumors" was adopted by the World Health Organization [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
         The clinical presentation, diagnosis, treatment, and prognosis of breast phyllodes tumors are discussed in this topic. Other benign (eg, fibroadenoma) or malignant lesions of the breast are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/806.html" rel="external">
          "Overview of benign breast diseases"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/744.html" rel="external">
          "Clinical features, diagnosis, and staging of newly diagnosed breast cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/737.html" rel="external">
          "Overview of the treatment of newly diagnosed, invasive, non-metastatic breast cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY AND RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Phyllodes tumors account for less than 1 percent of all breast neoplasms [
         <a href="#rid4">
          4,5
         </a>
         ]. Given their rarity, epidemiologic data are scant. In a study from Los Angeles county over a 17 year period, the average annual incidence rate of malignant phyllodes tumors was 2.1 per million women, and the incidence was higher in the Latina White population than in the non-Latina White population, Asian population, and African American population [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         The vast majority of phyllodes tumors occur in women, with a median age of presentation of 42 to 45 years (range 10 to 82 years) [
         <a href="#rid3">
          3,6-8
         </a>
         ]. Higher-grade tumors are more common in older patients [
         <a href="#rid9">
          9
         </a>
         ]. In men, phyllodes tumors usually occur in association with gynecomastia [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Phyllodes tumors have been associated with Li-Fraumeni syndrome, a rare autosomal dominant condition that is characterized by the development of multiple tumors [
         <a href="#rid10">
          10
         </a>
         ]. In a contemporary multicenter cohort of 550 patients with phyllodes tumors, only 34 underwent expanded multigene panel testing; a deleterious mutation was identified in about 10 percent (1
         <em>
          BRCA1
         </em>
         , 2
         <em>
          TP53
         </em>
         ); another two patients had a
         <em>
          BRCA2
         </em>
         variant of uncertain significance [
         <a href="#rid11">
          11
         </a>
         ]. The
         <em>
          TP53
         </em>
         mutation prevalence in this cohort exceeded the published baseline mutation rate of 2 percent in the general population of women with a diagnosis of breast adenocarcinoma. (See
         <a class="medical medical_review" href="/z/d/html/785.html" rel="external">
          "Overview of hereditary breast and ovarian cancer syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14255.html" rel="external">
          "Li-Fraumeni syndrome"
         </a>
         .)
        </p>
        <p>
         No other etiologic or predisposing factors have been linked to phyllodes tumors.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Phyllodes tumors are usually identified as a breast mass. On examination, most patients have a smooth, multinodular, well-defined, firm mass that is mobile and painless [
         <a href="#rid2">
          2,7
         </a>
         ]. Tumor size is variable, ranging from 1 to 41 cm (average 4 to 7 cm) [
         <a href="#rid4">
          4,8
         </a>
         ]. Shiny, stretched, and attenuated skin may be seen overlying a large tumor [
         <a href="#rid2">
          2
         </a>
         ]. Nipple retraction, ulceration, chest wall fixation, and bilateral diseases are rare but have been described for phyllodes tumors [
         <a href="#rid2">
          2,12
         </a>
         ].
        </p>
        <p>
         Phyllodes tumors may grow slowly or rapidly or exhibit a biphasic growth pattern. As they grow larger, phyllodes tumors can form a visible mass that distorts the contour of the breast or even cause pressure necrosis of the overlying skin.
        </p>
        <p>
         Although palpable axillary lymphadenopathy can be identified in up to 20 percent of patients, most are reactive; metastatic involvement of lymph nodes with phyllodes tumor is rare [
         <a href="#rid4">
          4,7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1255247731">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H3991724954">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Phyllodes tumors should be suspected when a patient presents with a large (&gt;3 cm), rapidly growing breast mass that is usually palpable. Although imaging features of a phyllodes tumor can be suggestive of fibroadenoma, the large size and history of rapid growth indicate otherwise. Phyllodes tumors can only be diagnosed histologically. Breast masses suspicious for a phyllodes tumor should undergo percutaneous core needle biopsy, with some being diagnosed after surgical excision of presumed fibroadenomas.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Phyllodes tumors can present as an abnormal finding on screening mammography. Suspicious lesions should be examined with breast ultrasound. Breast magnetic resonance imaging (MRI) may also be useful in select patients.
        </p>
        <p class="headingAnchor" id="H2176294316">
         <span class="h3">
          Mammography
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 20 percent of phyllodes tumors present as a nonpalpable mass identified on screening mammography [
         <a href="#rid13">
          13
         </a>
         ]. The typical appearance of a phyllodes tumor on mammography is a smooth, polylobulated mass resembling a fibroadenoma [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7561.html" rel="external">
          "Breast imaging for cancer screening: Mammography and ultrasonography"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/808.html" rel="external">
          "Diagnostic evaluation of suspected breast cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H955139034">
         <span class="h3">
          Ultrasonography
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with a palpable breast mass or suspicious lesion on mammography should have an ultrasound examination. Phyllodes lesions are primarily solid, hypoechoic, and well circumscribed on ultrasonography. Suspicion for a phyllodes tumor, rather than a fibroadenoma, is based on clinical features such as large tumor size at presentation and rapid growth [
         <a href="#rid2">
          2
         </a>
         ]. Although not always present, cystic areas within the mass on ultrasonography may increase the level of suspicion for phyllodes tumors [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1649634069">
         <span class="h3">
          Magnetic resonance imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Phyllodes tumors and fibroadenomas cannot be reliably differentiated by breast MRI [
         <a href="#rid15">
          15
         </a>
         ]. However, when a phyllodes tumor has been diagnosed on core biopsy, breast MRI may help determine the extent of disease and resectability in selected cases [
         <a href="#rid16">
          16
         </a>
         ]. However, the routine use of breast MRI in surgical planning for phyllodes tumors is controversial and not supported by data.
        </p>
        <p>
         Malignant phyllodes tumors are seen as well-circumscribed tumors with irregular walls, high signal intensity on T1-weighted images, and low signal intensity on T2-weighted images [
         <a href="#rid17">
          17
         </a>
         ]. Cystic change may be seen as well. A rapid enhancement pattern is seen more commonly with benign rather than malignant phyllodes tumors, which is the opposite of the pattern seen with adenocarcinomas of the breast [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Breast lesions suspicious for phyllodes tumors should undergo core biopsy, which is typically diagnostic. Compared with core biopsy, fine needle aspiration (FNA) is less accurate. If the core biopsy results are indeterminate or if there is clinical-pathologic discordance, an excisional biopsy should be performed.
        </p>
        <p class="headingAnchor" id="H3433769380">
         <span class="h3">
          Fine needle aspiration
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, FNA has been associated with a high false negative rate and low overall accuracy for the diagnosis of phyllodes tumors [
         <a href="#rid19">
          19
         </a>
         ]. Some experts, however, advocated paying special attention to three major cytological features (fibromyxoid stromal fragments with spindle nuclei, fibroblastic pavements, and spindle cells of fibroblastic nature) to improve the accuracy of FNA [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3422046703">
         <span class="h3">
          Core needle biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         On core needle biopsy, additional features can help distinguish phyllodes tumors from fibroadenomas. Such features include increased cellularity, mitosis, stromal overgrowth, and fragmentation (stroma with epithelium at one or both ends of the fragment). (See
         <a class="local">
          'Histologic'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3683833527">
         <span class="h3">
          Excisional biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the result of a core biopsy is indeterminate or discordant, an excisional biopsy is required. A core biopsy diagnosis of "cellular fibroadenoma," "cellular fibroepithelial lesion," or "fibroepithelial lesion with cellular stroma" should prompt surgical excision of the lesion, regardless of its appearance on imaging studies. Further pathologic characterization of the lesion may reveal a phyllodes tumor. Additionally, core biopsy has a 25 to 30 percent false negative rate when used to diagnose phyllodes tumors [
         <a href="#rid21">
          21-23
         </a>
         ]. Thus, if a solid mass has a benign core biopsy but subsequently grows rapidly or becomes symptomatic, an excisional biopsy is also indicated.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Pathology
         </span>
        </p>
        <p class="headingAnchor" id="H620029797">
         <span class="h3">
          Gross
         </span>
         <span class="headingEndMark">
          —
         </span>
         Grossly, phyllodes tumors may be indistinguishable from fibroadenomas. They are round to oval multinodular masses with a grayish-white appearance that resemble the head of a cauliflower  (
         <a class="graphic graphic_picture graphicRef51479" href="/z/d/graphic/51479.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. Phyllodes tumors grow radially, creating a pseudocapsule through which tongues of stroma may protrude and grow into adjacent breast tissue [
         <a href="#rid24">
          24
         </a>
         ]. Necrosis and hemorrhage can occur in larger tumors [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H386150560">
         <span class="h3">
          Microscopic
         </span>
         <span class="headingEndMark">
          —
         </span>
         Microscopically, the range of appearances covers the spectrum from resembling a benign fibroadenoma to a high-grade sarcoma. The characteristic leaf-like architecture consists of elongated cleft-like spaces that contain papillary projections of epithelial-lined stroma with varying degrees of hyperplasia and atypia  (
         <a class="graphic graphic_figure graphicRef78624" href="/z/d/graphic/78624.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. The stromal elements are a key component in differentiating phyllodes tumors from fibroadenomas and in differentiating a benign tumor from a malignant one [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="local">
          'Histologic'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3857138645">
         <span class="h3">
          Histologic
         </span>
         <span class="headingEndMark">
          —
         </span>
         Histologically, phyllodes tumors are classified as benign, borderline, or malignant based upon the assessment of four features [
         <a href="#rid2">
          2,4,6,7,25-28
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The degree of stromal cellular atypia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mitotic activity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infiltrative or circumscribed tumor margins
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence or absence of stromal overgrowth (ie, presence of pure stroma devoid of epithelium)
        </p>
        <p>
        </p>
        <p>
         Benign tumors are characterized by increased stromal cellularity with mild-to-moderate cellular atypia, circumscribed tumor margins and low mitotic rate (less than 4 mitoses per 10 high-power fields), and lack of stromal overgrowth.
        </p>
        <p>
         Borderline tumors have a greater degree of stromal cellularity and atypia, a mitotic rate of 4 to 9 mitoses per 10 high-power fields, microscopic infiltrative borders, and lack of stromal overgrowth.
        </p>
        <p>
         Malignant tumors are characterized by marked stromal cellularity and atypia, infiltrative margins, high mitotic rate (more than 10 mitoses per 10 high-power fields), and the presence of stromal overgrowth [
         <a href="#rid4">
          4,7,27-29
         </a>
         ].
        </p>
        <p>
         Of the four histologic features listed above, stromal overgrowth is most consistently associated with aggressive (metastatic) behavior [
         <a href="#rid1">
          1,30
         </a>
         ]. Most clinically malignant/metastatic phyllodes tumors have had overgrowth of one or several sarcomatous elements. These elements include liposarcoma, rhabdosarcoma, chondrosarcoma, and undifferentiated/unclassified sarcoma [
         <a href="#rid31">
          31,32
         </a>
         ].
        </p>
        <p>
         Undifferentiated/unclassified sarcoma was previously included within the terms of "malignant fibrous histiocytoma (MFH)" and "undifferentiated pleomorphic sarcoma (UPS)" but is now a separate soft tissue sarcoma category with an undifferentiated pleomorphic variant [
         <a href="#rid33">
          33
         </a>
         ]. Close examination of the stroma is imperative as the sarcomatous component may be present in only a small portion of the tumor [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14259.html" rel="external">
          "Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma", section on 'Histopathology'
         </a>
         .)
        </p>
        <p>
         Although the exact figures vary, more than 50 percent of phyllodes tumors are classified as benign and 25 percent as malignant in most large studies [
         <a href="#rid1">
          1,2,35-37
         </a>
         ].
        </p>
        <p>
         Histologic grades of phyllodes tumors have clinical implications and thus it is critical to have an accurate assessment. The College of American Pathologists developed a protocol to evaluate resection specimens of phyllodes tumor to standardize these classifications [
         <a href="#rid38">
          38
         </a>
         ]. Patients with benign tumors generally have better local control and disease-free survival compared with those with borderline or malignant tumors [
         <a href="#rid39">
          39
         </a>
         ]. Benign and borderline phyllodes tumors rarely recur following wide excision [
         <a href="#rid40">
          40
         </a>
         ]. (See
         <a class="local">
          'Breast surgery'
         </a>
         below.)
        </p>
        <p>
         Clinical behaviors of phyllodes tumors can also be influenced by factors other than histologic grades [
         <a href="#rid1">
          1,8
         </a>
         ]. In a study of 605 cases of phyllodes tumors, stromal atypia, mitoses, overgrowth, and surgical margin status (defined as complete, focally involved, and diffusely involved) were shown to be independent predictors of recurrence, with surgical margin status being the most important. A nomogram was developed by the use of a mathematical formula that could be applied to an individual patient to guide clinical decision making [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2513717418">
         <span class="h3">
          Molecular
         </span>
         <span class="headingEndMark">
          —
         </span>
         In phyllodes tumors, the status of tumor markers, such as p53, Ki-67, epidermal growth factor receptors, c-kit, and platelet-derived growth factor, has failed to predict outcomes [
         <a href="#rid34">
          34
         </a>
         ]. The expression of estrogen and progesterone receptors is common in the epithelial but not the stromal component of phyllodes tumors [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         On a molecular level, genetic heterogeneity has been observed intratumorally, with increasing numbers of aberrations coinciding with increased malignant potential [
         <a href="#rid42">
          42
         </a>
         ]. Some believe that phyllodes tumors arise from benign epithelial fibroadenomas due to their close histologic resemblance and molecular similarities [
         <a href="#rid2">
          2,3,43
         </a>
         ]. As an example, molecular analysis showed high frequencies of
         <em>
          MED12
         </em>
         (mediator complex subunit 12) mutations in both fibroadenomas and phyllodes tumors [
         <a href="#rid44">
          44
         </a>
         ]. In one study of 112 breast phyllodes tumors,
         <em>
          MED12
         </em>
         mutations were detected in 65, 66, and 43 percent of benign, borderline, and malignant phyllodes tumors, respectively [
         <a href="#rid45">
          45
         </a>
         ]. In another study using targeted next-generation sequencing, malignant phyllodes tumors were shown to harbor additional mutations in key tumor suppressor genes and oncogenes, such as
         <em>
          TP53
         </em>
         ,
         <em>
          RB1
         </em>
         ,
         <em>
          NF1
         </em>
         , and
         <em>
          CAN
         </em>
         [
         <a href="#rid46">
          46
         </a>
         ]. Although controversial, some thought that the acquisition of additional mutations explains the aggressive biological behaviors of malignant phyllodes tumors.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Phyllodes tumors should be completely excised; axillary lymph node dissection is not necessary. Adjuvant radiation therapy may benefit borderline or malignant, but not benign, tumors. Adjuvant chemotherapy is reserved for highly selected patients with large, high-risk, or recurrent malignant phyllodes tumors. Hormonal therapy is not used to treat phyllodes tumors. Given the rarity of the disease, treatment principles are based mainly on retrospective series and case reports.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Surgical resection
         </span>
        </p>
        <p class="headingAnchor" id="H3855289763">
         <span class="h3">
          Breast surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         A complete surgical excision is the standard of care for phyllodes tumors. Current National Comprehensive Cancer Network (NCCN) guidelines recommend excisional biopsy for benign phyllodes tumors and wide excision with intention of obtaining surgical margins of 1 cm or more for borderline and malignant phyllodes tumors, with a statement that a narrow margin is not an absolute indication for mastectomy when partial mastectomy fails to achieve a margin width of 1 cm or more [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1428165389">
         <span class="h4">
          Margins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Phyllodes tumors should be completely excised because most [
         <a href="#rid40">
          40,48-53
         </a>
         ], but not all [
         <a href="#rid37">
          37,54,55
         </a>
         ], studies have associated positive margins with unacceptably high local recurrence rates. In a multivariate survival analysis that included 172 patients with phyllodes tumors, a positive surgical margin was associated with an almost fourfold higher risk of a tumor-related event such as local recurrence or distant disease (hazard ratio [HR] 3.9, 95% CI 1.1-14.3) [
         <a href="#rid49">
          49
         </a>
         ]. Positive margins often occur when phyllodes tumors are misdiagnosed as fibroadenomas and either enucleated or locally excised without attention to margins [
         <a href="#rid4">
          4,5,13,14,25,39,40,50,56-59
         </a>
         ].
        </p>
        <p>
         However, the minimal acceptable margin beyond "clear" is controversial and depends on tumor grade [
         <a href="#rid13">
          13,48,49,60
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For benign phyllodes tumors, we aim for a clear margin but do not require a wide (eg, 1 cm) margin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Furthermore, emerging evidence suggests that a positive surgical margin may not be related to local recurrence for benign phyllodes tumors [
         <a href="#rid61">
          61
         </a>
         ]. A 2019 meta-analysis of 54 observational studies also found that a positive margin only correlated with a higher local recurrence risk for malignant, but not for benign and borderline, phyllodes tumors [
         <a href="#rid29">
          29
         </a>
         ]. Consequently, it has become controversial whether a negative margin should be strictly obtained for a benign phyllodes tumor [
         <a href="#rid37">
          37,62-64
         </a>
         ]. Some authors advocate only a "grossly complete excision," arguing that it would make re-excision of benign phyllodes tumors unnecessary when they are mistaken for fibroadenomas on core biopsy and excised with narrow margins or enucleated, as long as no gross tumor is left behind and regardless of microscopic margin status [
         <a href="#rid65">
          65
         </a>
         ]. This approach was also favored according to a Canadian National Consensus document after extensive review of available literature [
         <a href="#rid66">
          66
         </a>
         ]. Despite the controversy, however, it appears safe to accept a clear margin for benign phyllodes tumors without mandating re-excision for margins narrower than 1 cm.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For borderline or malignant phyllodes tumors, we also aim for a 1 cm margin. However, for patients with a clear but narrower than 1 cm margin, we determine the need for re-excision on a case-by-case basis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Surgical margins of ≥1 cm have been associated with a lower local recurrence rate in borderline and malignant phyllodes [
         <a href="#rid1">
          1,4,57
         </a>
         ]. In a retrospective review of 48 women with high-grade malignant phyllodes tumors, 10 patients were treated with local excision (margins &lt;1 cm), 14 with wide local excision (margins ≥1 cm), and 24 with mastectomy [
         <a href="#rid50">
          50
         </a>
         ]. At a median follow-up of nine years, the local recurrence rate was higher after local excision with narrow margins than after wide local excision (60 versus 28 percent). Local recurrence and cancer-specific survival were related to tumor size and excision margins. The average tumor size was 7.8 cm in this study. In another review of 125 malignant/borderline phyllodes tumors surgically treated at an academic cancer center, the 10-year locoregional recurrence rate was 12 percent. Patients with close (&lt;1 mm) or positive margins after surgery had a 33 percent 10 year locoregional recurrence rate, compared with 9 percent in those with negative margins, highlighting the importance of achieving at least a 1 mm margin after lumpectomy or mastectomy to minimize the risk of local recurrence [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         A multi-institutional cohort of 550 phyllodes tumors treated between 2007 and 2017 at 11 comprehensive cancer centers in the United States demonstrated wide variability in the management of margins for phyllodes tumors among surgeons with instances of omission of re-excision not only for close but also for positive margins. Interestingly, on univariate analysis, positive margins and margins &lt;2 mm were not associated with local recurrences when evaluating all three subtypes together. Multivariate analysis was not feasible, due to the small number of local failures. The authors conclude that these data suggest a shift toward less stringent margin recommendations on phyllodes tumors and a more individualized approach to margin management, which is supported by Canadian consensus guidelines [
         <a href="#rid37">
          37,66
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H475718765">
         <span class="h4">
          Breast-conserving surgery versus mastectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are limited data comparing breast-conserving surgery with mastectomy in the treatment of phyllodes tumors. However, where adequate margins can be achieved and adjuvant radiation therapy given, breast-conserving surgery seems to be as effective as total mastectomy in treating malignant phyllodes tumors [
         <a href="#rid1">
          1,4,13,67
         </a>
         ].
        </p>
        <p>
         In a study of 821 women with malignant phyllodes tumors from the Surveillance, Epidemiology, and End Results (SEER) database, mastectomy and wide local excision were performed in 52 and 48 percent, respectively [
         <a href="#rid13">
          13
         </a>
         ]. Compared with mastectomy, breast-conserving surgery was associated with equivalent or improved cause-specific survival regardless of tumor size.
        </p>
        <p>
         Mastectomy is generally not indicated for benign phyllodes unless the tumor is so large that breast-conserving surgery would result in suboptimal cosmetic outcomes.
        </p>
        <p class="headingAnchor" id="H4038139366">
         <span class="h3">
          Axillary surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Axillary lymph node involvement by phyllodes tumors is rarely reported, even when tumors are malignant [
         <a href="#rid5">
          5,7,13,37,58,68
         </a>
         ]. In the SEER database study cited above, only 8 of 498 women with known lymph node status had involved nodes [
         <a href="#rid13">
          13
         </a>
         ]. Thus, axillary surgery is rarely indicated in patients diagnosed with phyllodes tumors.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         When adequate surgical margins cannot be achieved because of tumor location, adjuvant radiation therapy (RT) should be administered, even after mastectomy. However, when adequate surgical margins can be achieved, there is less agreement about the need for adjuvant RT. We base our decision about adjuvant RT on tumor grade:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We do not suggest adjuvant RT for patients with benign phyllodes tumors that have been completely excised.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We suggest adjuvant RT for all patients undergoing breast-conserving surgery for a borderline or malignant phyllodes tumor as it substantially reduces local recurrence rates [
         <a href="#rid27">
          27,28,36,39,57,68,69
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In a meta-analysis of eight observational studies, adjuvant RT reduced local recurrences of borderline or malignant phyllodes tumors after breast-conserving surgery (HR 0.31, 95% CI -0.10 to 0.72) [
         <a href="#rid70">
          70
         </a>
         ]. The effect of adjuvant RT on local recurrences after mastectomy was less pronounced (HR 0.68, 95% CI -0.28 to 1.64). Another meta-analysis of 17 studies concluded that radiation is effective in decreasing local recurrence over surgery alone [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         Adjuvant RT has not been shown to improve survival compared with surgery alone. In a meta-analysis of eight observational studies, adjuvant RT had no effect on overall or disease-free survival [
         <a href="#rid70">
          70
         </a>
         ]. In a retrospective analysis of 3080 patients analyzed using the National Cancer Database, radiation did not improve overall survival [
         <a href="#rid72">
          72
         </a>
         ]. In a retrospective analysis using the SEER database, although there was no benefit in terms of overall survival for the group as a whole, there was a trend toward a survival benefit with the addition of adjuvant radiation in the subgroup of patients with tumors larger than 5 cm [
         <a href="#rid73">
          73,74
         </a>
         ].
        </p>
        <p>
         In clinical practice, the utilization of adjuvant RT for phyllodes tumors appears to be modest. In a retrospective review of the National Cancer Database that included 3120 patients with malignant phyllodes tumors, only 14 percent received adjuvant RT [
         <a href="#rid75">
          75
         </a>
         ]. Patients were more likely to receive radiation therapy if they were diagnosed later in the study, were 50 to 59 years old, had tumors &gt;10 cm, or had lymph nodes removed. In adjusted models, adjuvant radiation reduced local recurrence but did not impact survival after a median follow-up of 53 months.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on limited data, the role of systemic chemotherapy in phyllodes tumors is limited. Patients with benign or borderline phyllodes tumors are usually cured with surgery and should not be offered chemotherapy unless they develop unresectable metastases, which is exceedingly uncommon.
        </p>
        <p>
         The role of adjuvant chemotherapy in malignant phyllodes tumor is controversial and should not be routinely offered. Malignant phyllodes tumors are pathologically and clinically most similar to soft tissue sarcomas; however, localized malignant phyllodes tumors have a better prognosis than most high-grade sarcomas of similar stage [
         <a href="#rid76">
          76
         </a>
         ]. Thus, systemic chemotherapy should be considered for malignant phyllodes tumors with even more caution.
        </p>
        <p>
         There have been no randomized studies of adjuvant chemotherapy specifically for phyllodes tumors. In a small observational study, 28 patients with malignant phyllodes tumors were treated with either adjuvant
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         plus
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          dacarbazine
         </a>
         or observation alone after surgical resection based upon patient preference [
         <a href="#rid77">
          77
         </a>
         ]. Although the five-year relapse-free survival was not different between the two groups, the study was retrospective, nonrandomized, and underpowered. It did not utilize
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         in combination with doxorubicin (which is superior to dacarbazine plus doxorubicin in other soft tissue sarcomas).
        </p>
        <p>
         Based on experience and limited data, we recommend adjuvant chemotherapy only to a small minority of patients with high-risk (&gt;10 cm) or recurrent malignant phyllodes tumors who have excellent functional status and minimal comorbidities, and only after a thorough discussion about the risks, benefits, and controversial nature of such treatment. When systemic chemotherapy is indicated, malignant phyllodes tumors should be treated according to protocols designed for soft tissue sarcoma, such as an anthracycline plus
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         , rather than breast cancers. (See
         <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">
          "Overview of the initial treatment of metastatic soft tissue sarcoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Hormone therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hormone therapy is
         <strong>
          not
         </strong>
         effective against phyllodes tumors [
         <a href="#rid12">
          12,78
         </a>
         ]. Despite the presence of hormone receptors in the epithelial component of some phyllodes tumors, the stromal component is the principle neoplastic cell population responsible for the metastatic behavior. The stromal component primarily expresses estrogen receptor beta instead of estrogen receptor alpha, which is expressed by breast cancer [
         <a href="#rid79">
          79,80
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2374963716">
         <span class="h1">
          POSTTREATMENT SURVEILLANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the small number of patients with malignant phyllodes tumors of the breast, there are no evidence-based recommendations for surveillance after therapy [
         <a href="#rid81">
          81,82
         </a>
         ]. The following follow-up guidelines are adapted from those for soft tissue sarcoma (see
         <a class="medical medical_review" href="/z/d/html/7734.html" rel="external">
          "Overview of multimodality treatment for primary soft tissue sarcoma of the extremities and superficial trunk", section on 'Posttreatment sarcoma surveillance'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Since most recurrences occur in the first two years after treatment [
         <a href="#rid57">
          57
         </a>
         ], we perform a history and physical examination every six months for the first two years, then annually until five years. For patients with borderline and malignant phyllodes tumor, more frequent surveillance of the affected breast may be warranted. (See
         <a class="local">
          'Local recurrence'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with large (≥5 cm) or malignant phyllodes tumors are at higher risk of developing metastatic disease. For such patients, surveillance may be performed more frequently and with chest radiograph or chest computed tomography (CT) as recommended by the National Comprehensive Cancer Network (NCCN) on soft tissue sarcomas [
         <a href="#rid83">
          83
         </a>
         ]. (See
         <a class="local">
          'Metastatic disease'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who have not had mastectomy should resume routine breast surveillance. If suspicious lesions are found on imaging or breast examination, further imaging and/or biopsy may be required. (See
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3719457328">
         <span class="h1">
          RECURRENT AND METASTATIC DISEASES
         </span>
        </p>
        <p class="headingAnchor" id="H2434382320">
         <span class="h2">
          Local recurrence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite best surgical efforts, phyllodes tumors are known to recur locally with rates that vary with tumor grade. In earlier reports, benign, borderline, and malignant phyllodes tumors had local recurrence rates of 8, 21, and 36 percent, respectively [
         <a href="#rid40">
          40,57
         </a>
         ]. More contemporary series reported lower rates of local recurrence [
         <a href="#rid84">
          84
         </a>
         ]. As an example, a 2019 meta-analysis of 54 retrospective studies reported an overall local recurrence rate of 12 percent (95% CI 10-14 percent) and pooled local recurrence rates of 8, 13, and 18 percent for benign, borderline, and malignant tumors, respectively [
         <a href="#rid29">
          29
         </a>
         ]. In the previously mentioned multi-institutional cohort of 550 phyllodes tumors treated between 2007 and 2017 at 11 comprehensive cancer centers in the United States, local recurrences occurred in 1.3 percent of benign, 5.6 percent of borderline, and 6.9 percent of malignant phyllodes tumors with a median follow-up of 36.7 months [
         <a href="#rid37">
          37
         </a>
         ].
         <strong>
         </strong>
         Recurrent phyllodes tumors require surgical and/or radiation therapy. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
         When phyllodes tumors recur, they typically recur locally within two years of the initial excision [
         <a href="#rid4">
          4,12
         </a>
         ]. Some series have found that the time to local recurrence was shorter for malignant than for benign or borderline tumors [
         <a href="#rid4">
          4,34,40
         </a>
         ].
        </p>
        <p>
         Although recurrences typically have the same grade as the original tumors, there have been several case reports of benign tumors transforming into malignant ones upon recurrence [
         <a href="#rid1">
          1,8,36,85
         </a>
         ]. In one series of 293 phyllodes tumors, for example, six benign tumors recurred locally as malignant tumors [
         <a href="#rid8">
          8
         </a>
         ]. A systematic review of 54 retrospective studies reported some 26 percent (range 13 to 38) of benign and 21 percent (8 to 33 percent) of borderline tumors that recurred underwent upgrade [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         Recurrent phyllodes tumors are treated with surgery and/or radiation, with the goal of avoiding re-recurrence and the need for additional surgical intervention. Resectable recurrent disease is treated with either re-excision with wide margins or mastectomy, followed by radiation therapy (RT). Unresectable recurrences are treated with palliative radiation alone [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="local">
          'Surgical resection'
         </a>
         above and
         <a class="local">
          'Radiation therapy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1894927120">
         <span class="h2">
          Metastatic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Metastatic disease has been reported in 13 to 40 percent of patients with phyllodes tumors [
         <a href="#rid1">
          1,2,4,19
         </a>
         ]. The median overall survival ranges from approximately 11 to 24 months in patients who develop metastatic disease [
         <a href="#rid86">
          86,87
         </a>
         ].
        </p>
        <p>
         Phyllodes tumors metastasize most often to the lungs, although given their hematogenous spread, bones and nearly all organs can be affected. Tumors that metastasize are typically large (≥5 cm) or have malignant histologic features (see
         <a class="local">
          'Histologic'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 101 patients, eight developed distant metastases, seven of whom had malignant tumors and one benign [
         <a href="#rid1">
          1
         </a>
         ]. All tumors had stromal overgrowth, and six were ≥5 cm in size.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another retrospective review of 293 phyllodes tumors treated between 1954 and 2005, five patients developed distant disease. All tumors that metastasized had one or more malignant histologic features such as infiltrative borders, marked stromal overgrowth, marked stromal cellularity, high mitotic count, and necrosis and were ≥7 cm in size [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         For patients with metastatic disease, chemotherapy may be administered with palliative intent based upon treatment guidelines for soft tissue sarcomas [
         <a href="#rid4">
          4,88
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Most regimens have limited or short-lived benefit, with the highest levels of efficacy seen in
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         and alkylating-based therapies [
         <a href="#rid86">
          86,89
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two malignant phyllodes-specific case series reported highest response rates to an anthracycline given in combination with
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         (45 and 56 percent), but with a limited median progression-free survival (5.7 and 9.1 months) [
         <a href="#rid90">
          90,91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other regimens such as single agent anthracycline or
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         , gemcitabine-based regimens,
         <a class="drug drug_general" data-topicid="9513" href="/z/d/drug information/9513.html" rel="external">
          trabectedin
         </a>
         , and tyrosine kinase inhibitors yielded lower rates of activity [
         <a href="#rid90">
          90,91
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Given the paucity of efficacious agents in the metastatic setting, patients should be referred for investigational treatments in clinical trials [
         <a href="#rid86">
          86
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">
          "Overview of the initial treatment of metastatic soft tissue sarcoma"
         </a>
         .)
        </p>
        <p>
         Similar to metastatic soft tissue sarcoma, there may be a role for metastasectomy in select cases with oligometastatic disease. As an example, pulmonary metastases of phyllodes tumors should be resected when technically feasible in the appropriate context. (See
         <a class="medical medical_review" href="/z/d/html/7738.html" rel="external">
          "Surgical treatment and other localized therapy for metastatic soft tissue sarcoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2166812580">
         <span class="h1">
          SURVIVAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of patients with benign and borderline phyllodes tumors are cured by surgery. The survival rate for malignant phyllodes tumors is approximately 60 to 80 percent at five years [
         <a href="#rid1">
          1,13,56
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The impact of histology on survival was explored in the SArcoma and PHYllode Retrospective (SAPHYR) Study, a retrospective study of 70 patients with primary breast sarcomas and phyllodes tumors treated from 1966 to 2004 [
         <a href="#rid56">
          56
         </a>
         ]. The overall three-year survival rate for combined benign and borderline tumors was 100 percent. The overall three-year survival rate for malignant phyllodes tumors was 54 percent, similar to that of nonangiosarcoma primary breast sarcomas (60 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similarly, in a retrospective study of 101 patients treated between 1944 and 1998, the five-year overall survival rate for patients with benign/borderline and malignant tumors was 91 and 82 percent, respectively [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a contemporary series of 125 malignant/borderline phyllodes tumors surgically treated at an academic cancer center, uniformly poor pathologic features, including stromal cellularity, stromal overgrowth, infiltrative borders, and ≥10 mitoses per 10 high-powered fields, were identified in 20 percent of malignant phyllodes tumors and predicted for a poor prognosis, with all distant recurrences occurring in this group and with a 63 percent 10 year disease-specific survival. The 10 year disease-specific survival for malignant/borderline phyllodes patients without uniformly poor pathologic features was 100 percent [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H853849061">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/121714.html" rel="external">
          "Society guideline links: Evaluation of breast problems"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H505077494">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Phyllodes tumors are uncommon fibroepithelial breast tumors that are capable of a diverse range of biologic behaviors. Most phyllodes tumors present as smooth, multinodular, painless breast lumps. While they can be confused for fibroadenomas, phyllodes tumors typically have larger sizes and grow rapidly. Twenty percent of phyllodes tumors present as abnormal findings on screening mammography. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging
         </strong>
         – The typical appearance of a phyllodes tumor on mammography is a smooth, polylobulated mass. On ultrasound examination, these lesions are solid, hypoechoic, and well circumscribed. The presence of cystic areas within the mass may increase the level of suspicion for phyllodes tumors. (See
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Biopsy
         </strong>
         – Breast masses suspicious for phyllodes tumors should undergo core biopsy; fine needle aspiration is less accurate. If the core biopsy results are indeterminate or if there is clinical-pathologic discordance, an excisional biopsy should be performed. (See
         <a class="local">
          'Biopsy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgical excision
         </strong>
         – A complete surgical excision is the standard of care for all phyllodes tumors; however, the minimal acceptable margin beyond "clear" depends on tumor grade (see
         <a class="local">
          'Breast surgery'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For
         <strong>
          benign phyllodes
         </strong>
         tumors, we aim for a clear margin. A wide (eg, 1 cm) negative margin is not required.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For
         <strong>
          borderline or malignant
         </strong>
         phyllodes tumors, we suggest a 1 cm negative margin (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However, we will determine whether to re-excise to a 1 cm negative margin on a case-by-case basis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          No routine axillary dissection
         </strong>
         – For most patients with phyllodes tumors, we suggest
         <strong>
          not
         </strong>
         performing routine axillary dissection (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Axillary lymph node involvement is rare, even with malignant tumors. (See
         <a class="local">
          'Surgical resection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adjuvant radiotherapy
         </strong>
         – Following surgical excision of a phyllodes tumor, the need for adjuvant radiotherapy also depends on tumor grade (see
         <a class="local">
          'Radiation therapy'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For
         <strong>
          benign
         </strong>
         phyllodes tumors that are completely excised, we suggest not performing adjuvant radiotherapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For
         <strong>
          borderline or malignant
         </strong>
         phyllodes tumors, we suggest performing adjuvant radiotherapy, even after a complete excision (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Radiation therapy substantially reduces the local recurrence rates of these tumors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adjuvant chemotherapy
         </strong>
         – The role of adjuvant chemotherapy in phyllodes tumors is reserved for highly selected patients. Chemotherapeutic agents should be chosen based upon treatment guidelines for soft tissue sarcomas, rather than breast cancer. (See
         <a class="local">
          'Chemotherapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          No hormonal therapy
         </strong>
         – Hormone therapy is
         <strong>
          not
         </strong>
         effective against phyllodes tumors. (See
         <a class="local">
          'Hormone therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Posttreatment surveillance
         </strong>
         – We perform a history and physical examination every six months for two years after the initial treatment of phyllodes tumors, then annually until five years. Patients at higher risk for developing metastatic diseases (≥5 cm or malignant tumors) may require more frequent surveillance with chest radiograph or chest computed tomography (CT) per guidelines for soft tissue sarcoma. (See
         <a class="local">
          'Posttreatment surveillance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recurrence and metastasis
         </strong>
         – Locally recurrent phyllodes tumors that are resectable should undergo wide re-excision followed by adjuvant radiotherapy. Unresectable recurrences are palliated with radiation therapy. Resectable pulmonary metastasis should be resected; unresectable metastatic phyllodes tumors are palliated with chemotherapy according to soft tissue sarcoma protocols. (See
         <a class="local">
          'Recurrent and metastatic diseases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Survival
         </strong>
         – The majority of patients with benign and borderline phyllodes tumors are cured by surgery. The survival rate for malignant phyllodes tumors is approximately 60 to 80 percent at five years. (See
         <a class="local">
          'Survival'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Chaney AW, Pollack A, McNeese MD, et al. Primary treatment of cystosarcoma phyllodes of the breast. Cancer 2000; 89:1502.
          </a>
         </li>
         <li class="breakAll">
          Calhoun K, Allison KH, Kim JN, et al.. Phyllodes tumors. In: Diseases of the breast, Harris J, Lippman ME, Morrow M, Osborne KC (Eds), Lippincott Williams and Wilkins, 2014.
         </li>
         <li class="breakAll">
          Tavassoli FA, Devilee P. and genetics of tumours of the breast and female genital organs. In: World Health Organization Classification of Tumours, IARC Press, Lyons 2003. p.99.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reinfuss M, Mituś J, Duda K, et al. The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Cancer 1996; 77:910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geisler DP, Boyle MJ, Malnar KF, et al. Phyllodes tumors of the breast: a review of 32 cases. Am Surg 2000; 66:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein L, Deapen D, Ross RK. The descriptive epidemiology of malignant cystosarcoma phyllodes tumors of the breast. Cancer 1993; 71:3020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norris HJ, Taylor HB. Relationship of histologic features to behavior of cystosarcoma phyllodes. Analysis of ninety-four cases. Cancer 1967; 20:2090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrio AV, Clark BD, Goldberg JI, et al. Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol 2007; 14:2961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karim RZ, Gerega SK, Yang YH, et al. Phyllodes tumours of the breast: a clinicopathological analysis of 65 cases from a single institution. Breast 2009; 18:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birch JM, Alston RD, McNally RJ, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 2001; 20:4621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenberger LH, Thomas SM, Nimbkar SN, et al. Germline Genetic Mutations in a Multi-center Contemporary Cohort of 550 Phyllodes Tumors: An Opportunity for Expanded Multi-gene Panel Testing. Ann Surg Oncol 2020; 27:3633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Telli ML, Horst KC, Guardino AE, et al. Phyllodes tumors of the breast: natural history, diagnosis, and treatment. J Natl Compr Canc Netw 2007; 5:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macdonald OK, Lee CM, Tward JD, et al. Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer 2006; 107:2127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mangi AA, Smith BL, Gadd MA, et al. Surgical management of phyllodes tumors. Arch Surg 1999; 134:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wurdinger S, Herzog AB, Fischer DR, et al. Differentiation of phyllodes breast tumors from fibroadenomas on MRI. AJR Am J Roentgenol 2005; 185:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan H, Zhang S, Liu H, et al. Imaging findings in phyllodes tumors of the breast. Eur J Radiol 2012; 81:e62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yabuuchi H, Soeda H, Matsuo Y, et al. Phyllodes tumor of the breast: correlation between MR findings and histologic grade. Radiology 2006; 241:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farria DM, Gorczyca DP, Barsky SH, et al. Benign phyllodes tumor of the breast: MR imaging features. AJR Am J Roentgenol 1996; 167:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacklin RK, Ridgway PF, Ziprin P, et al. Optimising preoperative diagnosis in phyllodes tumour of the breast. J Clin Pathol 2006; 59:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Hag IA, Aodah A, Kollur SM, et al. Cytological clues in the distinction between phyllodes tumor and fibroadenoma. Cancer Cytopathol 2010; 118:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dillon MF, Quinn CM, McDermott EW, et al. Needle core biopsy in the diagnosis of phyllodes neoplasm. Surgery 2006; 140:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AH. Recent developments in the histological diagnosis of spindle cell carcinoma, fibromatosis and phyllodes tumour of the breast. Histopathology 2008; 52:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AH, Hodi Z, Ellis IO, Elston CW. Histological features useful in the distinction of phyllodes tumour and fibroadenoma on needle core biopsy of the breast. Histopathology 2007; 51:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan BY, Acs G, Apple SK, et al. Phyllodes tumours of the breast: a consensus review. Histopathology 2016; 68:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Roos WK, Kaye P, Dent DM. Factors leading to local recurrence or death after surgical resection of phyllodes tumours of the breast. Br J Surg 1999; 86:396.
          </a>
         </li>
         <li class="breakAll">
          Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO Classification of Tumours of the Breast, 4th ed, World Health Organization, 2012.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawkins RE, Schofield JB, Fisher C, et al. The clinical and histologic criteria that predict metastases from cystosarcoma phyllodes. Cancer 1992; 69:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fajdić J, Gotovac N, Hrgović Z, et al. Phyllodes tumors of the breast diagnostic and therapeutic dilemmas. Onkologie 2007; 30:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu Y, Chen Y, Zhu L, et al. Local Recurrence of Benign, Borderline, and Malignant Phyllodes Tumors of the Breast: A Systematic Review and Meta-analysis. Ann Surg Oncol 2019; 26:1263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pietruszka M, Barnes L. Cystosarcoma phyllodes: a clinicopathologic analysis of 42 cases. Cancer 1978; 41:1974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powell CM, Rosen PP. Adipose differentiation in cystosarcoma phyllodes. A study of 14 cases. Am J Surg Pathol 1994; 18:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guerrero MA, Ballard BR, Grau AM. Malignant phyllodes tumor of the breast: review of the literature and case report of stromal overgrowth. Surg Oncol 2003; 12:27.
          </a>
         </li>
         <li class="breakAll">
          Fletcher CDM, Chibon F, Mertens F. Undifferentiated/unclassified sarcomas. In: WHO Classification of Tumours of Soft Tissue and Bone, 4th ed, Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (Eds), IARC, Lyon 2013. p.236.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carter BA, Page DL. Phyllodes tumor of the breast: local recurrence versus metastatic capacity. Hum Pathol 2004; 35:1051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mituś JW, Blecharz P, Reinfuss M, et al. Changes in the clinical characteristics, treatment options, and therapy outcomes in patients with phyllodes tumor of the breast during 55 years of experience. Med Sci Monit 2013; 19:1183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parker SJ, Harries SA. Phyllodes tumours. Postgrad Med J 2001; 77:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenberger LH, Thomas SM, Nimbkar SN, et al. Contemporary Multi-Institutional Cohort of 550 Cases of Phyllodes Tumors (2007-2017) Demonstrates a Need for More Individualized Margin Guidelines. J Clin Oncol 2021; 39:178.
          </a>
         </li>
         <li class="breakAll">
          Protocol for the examination of resection specimens from
patients with phyllodes tumor of the breast. College of American Pathologists. Available at: https://documents.cap.org/protocols/Breast.Phyllodes_1.1.0.1.REL_CAPCP.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belkacémi Y, Bousquet G, Marsiglia H, et al. Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys 2008; 70:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barth RJ Jr. Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors. Breast Cancer Res Treat 1999; 57:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan PH, Thike AA, Tan WJ, et al. Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. J Clin Pathol 2012; 65:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karim RZ, O'Toole SA, Scolyer RA, et al. Recent insights into the molecular pathogenesis of mammary phyllodes tumours. J Clin Pathol 2013; 66:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuijper A, Buerger H, Simon R, et al. Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. J Pathol 2002; 197:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan J, Ong CK, Lim WK, et al. Genomic landscapes of breast fibroepithelial tumors. Nat Genet 2015; 47:1341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng CC, Tan J, Ong CK, et al. MED12 is frequently mutated in breast phyllodes tumours: a study of 112 cases. J Clin Pathol 2015; 68:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cani AK, Hovelson DH, McDaniel AS, et al. Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors. Mol Cancer Res 2015; 13:613.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology (NCCN Guidelines). Phyllodes tumor. Version 1.2021. Available at: www.nccn.org (Accessed on February 21, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jang JH, Choi MY, Lee SK, et al. Clinicopathologic risk factors for the local recurrence of phyllodes tumors of the breast. Ann Surg Oncol 2012; 19:2612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spitaleri G, Toesca A, Botteri E, et al. Breast phyllodes tumor: a review of literature and a single center retrospective series analysis. Crit Rev Oncol Hematol 2013; 88:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kapiris I, Nasiri N, A'Hern R, et al. Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high-grade malignant phyllodes tumours of the breast. Eur J Surg Oncol 2001; 27:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toussaint A, Piaget-Rossel R, Stormacq C, et al. Width of margins in phyllodes tumors of the breast: the controversy drags on?-a systematic review and meta-analysis. Breast Cancer Res Treat 2021; 185:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neron M, Sajous C, Thezenas S, et al. Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study. Ann Surg Oncol 2020; 27:1818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spanheimer PM, Murray MP, Zabor EC, et al. Long-Term Outcomes After Surgical Treatment of Malignant/Borderline Phyllodes Tumors of the Breast. Ann Surg Oncol 2019; 26:2136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yom CK, Han W, Kim SW, et al. Reappraisal of conventional risk stratification for local recurrence based on clinical outcomes in 285 resected phyllodes tumors of the breast. Ann Surg Oncol 2015; 22:2912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Genco IS, Purohit V, Hackman K, et al. Benign and borderline phyllodes tumors of the breast: Clinicopathologic analysis of 205 cases with emphasis on the surgical margin status and local recurrence rate. Ann Diagn Pathol 2021; 51:151708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Confavreux C, Lurkin A, Mitton N, et al. Sarcomas and malignant phyllodes tumours of the breast--a retrospective study. Eur J Cancer 2006; 42:2715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barth RJ Jr, Wells WA, Mitchell SE, Cole BF. A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol 2009; 16:2288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen WH, Cheng SP, Tzen CY, et al. Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases. J Surg Oncol 2005; 91:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhargav PR, Mishra A, Agarwal G, et al. Phyllodes tumour of the breast: clinicopathological analysis of recurrent vs. non-recurrent cases. Asian J Surg 2009; 32:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moutte A, Chopin N, Faure C, et al. Surgical Management of Benign and Borderline Phyllodes Tumors of the Breast. Breast J 2016; 22:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ouyang Q, Li S, Tan C, et al. Benign Phyllodes Tumor of the Breast Diagnosed After Ultrasound-Guided Vacuum-Assisted Biopsy: Surgical Excision or Wait-and-Watch? Ann Surg Oncol 2016; 23:1129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moo TA, Alabdulkareem H, Tam A, et al. Association Between Recurrence and Re-Excision for Close and Positive Margins Versus Observation in Patients with Benign Phyllodes Tumors. Ann Surg Oncol 2017; 24:3088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cowan ML, Argani P, Cimino-Mathews A. Benign and low-grade fibroepithelial neoplasms of the breast have low recurrence rate after positive surgical margins. Mod Pathol 2016; 29:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noordman PCW, Klioueva NM, Weimann MN, et al. Phyllodes tumors of the breast: a retrospective analysis of 57 cases. Breast Cancer Res Treat 2020; 181:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li GZ, Raut CP, Hunt KK, et al. Breast Sarcomas, Phyllodes Tumors, and Desmoid Tumors: Epidemiology, Diagnosis, Staging, and Histology-Specific Management Considerations. Am Soc Clin Oncol Educ Book 2021; 41:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogach J, Sriskandarajah A, Wright FC, et al. Phyllodes Tumors of the Breast: Canadian National Consensus Document Using Modified Delphi Methodology. Ann Surg Oncol 2023; 30:6386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onkendi EO, Jimenez RE, Spears GM, et al. Surgical treatment of borderline and malignant phyllodes tumors: the effect of the extent of resection and tumor characteristics on patient outcome. Ann Surg Oncol 2014; 21:3304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soumarová R, Seneklová Z, Horová H, et al. Retrospective analysis of 25 women with malignant cystosarcoma phyllodes--treatment results. Arch Gynecol Obstet 2004; 269:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pezner RD, Schultheiss TE, Paz IB. Malignant phyllodes tumor of the breast: local control rates with surgery alone. Int J Radiat Oncol Biol Phys 2008; 71:710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeng S, Zhang X, Yang D, et al. Effects of adjuvant radiotherapy on borderline and malignant phyllodes tumors: A systematic review and meta-analysis. Mol Clin Oncol 2015; 3:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chao X, Chen K, Zeng J, et al. Adjuvant radiotherapy and chemotherapy for patients with breast phyllodes tumors: a systematic review and meta-analysis. BMC Cancer 2019; 19:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oladeru OT, Yang DD, Ma SJ, et al. Patterns of care and predictors of adjuvant radiation therapy in phyllodes tumor of the breast. Breast J 2020; 26:1352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao W, Tian Q, Zhao A, et al. The role of adjuvant radiotherapy in patients with malignant phyllodes tumor of the breast: a propensity-score matching analysis. Breast Cancer 2021; 28:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barth RJ Jr. Borderline and Malignant Phyllodes Tumors: How Often do They Locally Recur and is There Anything we can do About it? Ann Surg Oncol 2019; 26:1973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gnerlich JL, Williams RT, Yao K, et al. Utilization of radiotherapy for malignant phyllodes tumors: analysis of the National Cancer Data Base, 1998-2009. Ann Surg Oncol 2014; 21:1222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutnik L, Ren Y, Thomas SM, et al. Malignant phyllodes tumor and primary breast sarcoma; distinct rare tumors of the breast. J Surg Oncol 2022; 125:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morales-Vásquez F, Gonzalez-Angulo AM, Broglio K, et al. Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast. Breast J 2007; 13:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burton GV, Hart LL, Leight GS Jr, et al. Cystosarcoma phyllodes. Effective therapy with cisplatin and etoposide chemotherapy. Cancer 1989; 63:2088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sapino A, Bosco M, Cassoni P, et al. Estrogen receptor-beta is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast. Mod Pathol 2006; 19:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tse GM, Lee CS, Kung FY, et al. Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathologic grade of the tumor: a multicenter study of 143 cases. Am J Clin Pathol 2002; 118:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel SR, Zagars GK, Pisters PW. The follow-up of adult soft-tissue sarcomas. Semin Oncol 2003; 30:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grabowski J, Salzstein SL, Sadler GR, Blair SL. Malignant phyllodes tumors: a review of 752 cases. Am Surg 2007; 73:967.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology (NCCN Guidelines). Soft Tissue Sarcoma. Version 2.2016. Available at: www.nccn.org (Accessed on February 22, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borhani-Khomani K, Talman ML, Kroman N, Tvedskov TF. Risk of Local Recurrence of Benign and Borderline Phyllodes Tumors: A Danish Population-Based Retrospective Study. Ann Surg Oncol 2016; 23:1543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen R, Nixon D, York M, Coleman J. Successful chemotherapy for cystosarcoma phyllodes in a young woman. Arch Intern Med 1985; 145:1127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neron M, Sajous C, Thezenas S, et al. Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study. Ann Surg Oncol 2020; 27:1693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samii E, Hurni Y, Huber D. Management and Outcomes of Metastatic and Recurrent Malignant Phyllodes Tumors of the Breast: A Systematic Literature Review. Eur J Breast Health 2023; 19:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawkins RE, Schofield JB, Wiltshaw E, et al. Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes. Cancer 1992; 69:2271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mituś JW, Blecharz P, Walasek T, et al. Treatment of Patients with Distant Metastases from Phyllodes Tumor of the Breast. World J Surg 2016; 40:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palassini E, Mir O, Grignani G, et al. Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses. Breast Cancer Res Treat 2022; 192:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parkes A, Wang WL, Patel S, et al. Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Res Treat 2021; 186:871.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 793 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11013364" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Primary treatment of cystosarcoma phyllodes of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11013364" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Primary treatment of cystosarcoma phyllodes of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11013364" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Primary treatment of cystosarcoma phyllodes of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8608483" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10776873" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Phyllodes tumors of the breast: a review of 32 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8387873" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The descriptive epidemiology of malignant cystosarcoma phyllodes tumors of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4294565" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Relationship of histologic features to behavior of cystosarcoma phyllodes. Analysis of ninety-four cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17562113" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19329316" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Phyllodes tumours of the breast: a clinicopathological analysis of 65 cases from a single institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11498785" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Relative frequency and morphology of cancers in carriers of germline TP53 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32504368" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Germline Genetic Mutations in a Multi-center Contemporary Cohort of 550 Phyllodes Tumors: An Opportunity for Expanded Multi-gene Panel Testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17439760" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Phyllodes tumors of the breast: natural history, diagnosis, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16998937" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10323420" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Surgical management of phyllodes tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16247156" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Differentiation of phyllodes breast tumors from fibroadenomas on MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21353414" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Imaging findings in phyllodes tumors of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17032912" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Phyllodes tumor of the breast: correlation between MR findings and histologic grade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8659370" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Benign phyllodes tumor of the breast: MR imaging features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16461806" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Optimising preoperative diagnosis in phyllodes tumour of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20094997" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Cytological clues in the distinction between phyllodes tumor and fibroadenoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17084721" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Needle core biopsy in the diagnosis of phyllodes neoplasm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18171416" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Recent developments in the histological diagnosis of spindle cell carcinoma, fibromatosis and phyllodes tumour of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17727475" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Histological features useful in the distinction of phyllodes tumour and fibroadenoma on needle core biopsy of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26768026" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Phyllodes tumours of the breast: a consensus review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10201787" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Factors leading to local recurrence or death after surgical resection of phyllodes tumours of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10201787" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Factors leading to local recurrence or death after surgical resection of phyllodes tumours of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1309302" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The clinical and histologic criteria that predict metastases from cystosarcoma phyllodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17341897" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Phyllodes tumors of the breast diagnostic and therapeutic dilemmas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30617873" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Local Recurrence of Benign, Borderline, and Malignant Phyllodes Tumors of the Breast: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/206344" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Cystosarcoma phyllodes: a clinicopathologic analysis of 42 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8017566" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Adipose differentiation in cystosarcoma phyllodes. A study of 14 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12689668" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Malignant phyllodes tumor of the breast: review of the literature and case report of stromal overgrowth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12689668" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Malignant phyllodes tumor of the breast: review of the literature and case report of stromal overgrowth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15343504" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Phyllodes tumor of the breast: local recurrence versus metastatic capacity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24356679" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Changes in the clinical characteristics, treatment options, and therapy outcomes in patients with phyllodes tumor of the breast during 55 years of experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11423590" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Phyllodes tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33301374" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Contemporary Multi-Institutional Cohort of 550 Cases of Phyllodes Tumors (2007-2017) Demonstrates a Need for More Individualized Margin Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33301374" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Contemporary Multi-Institutional Cohort of 550 Cases of Phyllodes Tumors (2007-2017) Demonstrates a Need for More Individualized Margin Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17931796" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Phyllodes tumor of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10617306" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22049216" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23404800" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Recent insights into the molecular pathogenesis of mammary phyllodes tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12210075" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26437033" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Genomic landscapes of breast fibroepithelial tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26018969" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : MED12 is frequently mutated in breast phyllodes tumours: a study of 112 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25593300" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25593300" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22476816" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Clinicopathologic risk factors for the local recurrence of phyllodes tumors of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23871531" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Breast phyllodes tumor: a review of literature and a single center retrospective series analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11735168" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high-grade malignant phyllodes tumours of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32935237" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Width of margins in phyllodes tumors of the breast: the controversy drags on?-a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31989361" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30783853" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Long-Term Outcomes After Surgical Treatment of Malignant/Borderline Phyllodes Tumors of the Breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25652050" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Reappraisal of conventional risk stratification for local recurrence based on clinical outcomes in 285 resected phyllodes tumors of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33513547" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Benign and borderline phyllodes tumors of the breast: Clinicopathologic analysis of 205 cases with emphasis on the surgical margin status and local recurrence rate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17023158" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Sarcomas and malignant phyllodes tumours of the breast--a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19424757" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16118768" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19892625" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Phyllodes tumour of the breast: clinicopathological analysis of recurrent vs. non-recurrent cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27265474" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Surgical Management of Benign and Borderline Phyllodes Tumors of the Breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26577125" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Benign Phyllodes Tumor of the Breast Diagnosed After Ultrasound-Guided Vacuum-Assisted Biopsy: Surgical Excision or Wait-and-Watch?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28766221" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Association Between Recurrence and Re-Excision for Close and Positive Margins Versus Observation in Patients with Benign Phyllodes Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26743469" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Benign and low-grade fibroepithelial neoplasms of the breast have low recurrence rate after positive surgical margins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32277376" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Phyllodes tumors of the breast: a retrospective analysis of 57 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34010054" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Breast Sarcomas, Phyllodes Tumors, and Desmoid Tumors: Epidemiology, Diagnosis, Staging, and Histology-Specific Management Considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37556009" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Phyllodes Tumors of the Breast: Canadian National Consensus Document Using Modified Delphi Methodology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25034817" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Surgical treatment of borderline and malignant phyllodes tumors: the effect of the extent of resection and tumor characteristics on patient outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15205980" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Retrospective analysis of 25 women with malignant cystosarcoma phyllodes--treatment results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18234448" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Malignant phyllodes tumor of the breast: local control rates with surgery alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26137284" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Effects of adjuvant radiotherapy on borderline and malignant phyllodes tumors: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31014268" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Adjuvant radiotherapy and chemotherapy for patients with breast phyllodes tumors: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32275108" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Patterns of care and predictors of adjuvant radiation therapy in phyllodes tumor of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32748225" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : The role of adjuvant radiotherapy in patients with malignant phyllodes tumor of the breast: a propensity-score matching analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30863938" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Borderline and Malignant Phyllodes Tumors: How Often do They Locally Recur and is There Anything we can do About it?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24306659" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Utilization of radiotherapy for malignant phyllodes tumors: analysis of the National Cancer Data Base, 1998-2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35179788" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Malignant phyllodes tumor and primary breast sarcoma; distinct rare tumors of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17983394" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2541882" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Cystosarcoma phyllodes. Effective therapy with cisplatin and etoposide chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16554735" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Estrogen receptor-beta is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12375638" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathologic grade of the tumor: a multicenter study of 143 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12870143" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : The follow-up of adult soft-tissue sarcomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17983058" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Malignant phyllodes tumors: a review of 752 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17983058" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Malignant phyllodes tumors: a review of 752 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26714948" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Risk of Local Recurrence of Benign and Borderline Phyllodes Tumors: A Danish Population-Based Retrospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2988474" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Successful chemotherapy for cystosarcoma phyllodes in a young woman.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31773519" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37415652" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Management and Outcomes of Metastatic and Recurrent Malignant Phyllodes Tumors of the Breast: A Systematic Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1314127" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26464157" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Treatment of Patients with Distant Metastases from Phyllodes Tumor of the Breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35150367" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33575859" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Outcomes of systemic therapy in metastatic phyllodes tumor of the breast.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
